This interaction may play a key role in promoting fibrosis, suggesting that the synergistic effects of sphingolipid and IL-17 signaling pathways could serve as a potential strategy for targeted therapy in WD liver fibrosis. This evidence concerns the gene IL17A and Wilson disease.